Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;12(5):497-501.
doi: 10.11909/j.issn.1671-5411.2015.05.003.

Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly?

Bartosz Olechowski  1 , Rebecca Sands  2 , Donah Zachariah  2 , Neil P Andrews  2 , Richard Balasubramaniam  1 , Mark Sopher  1 , John Paisey  1 , Paul R Kalra  2
Affiliations

Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly?

Bartosz Olechowski et al. J Geriatr Cardiol. 2015 Sep.

Abstract

Objective: To evaluate whether cardiac resynchronisation therapy (CRT) implantation was feasible and safe in octogenarians and the association with symptoms.

Methods: Consecutive patients undergoing CRT implantation were recruited from two UK centers. Patients grouped according to age: < 80 & ≥ 80 years. Baseline demographics, complications and outcomes were compared between those groups.

Results: A total of 439 patients were included in this study, of whom 26% were aged ≥ 80 years. Octogenarians more often received cardiac resynchronization therapy pacemaker in comparison to cardiac resynchronisation therapy-defibrillator. Upgrade from pacemaker was common in both groups (16% < 80 years vs. 22% ≥ 80 years, P = NS). Co-morbidities were similarly common in both groups (overall diabetes: 25%, atrial fibrillation: 23%, hypertension: 45%). More patient age ≥ 80 years had significant chronic kidney disease (CKD, estimated glomerular filtration rate < 45 mL/min per 1.73 m(2), 44% vs. 22%, P < 0.01). Overall complication rates (any) were similar in both groups (16% vs. 17%, P = NS). Both groups demonstrated symptomatic benefit. One-year mortality rates were almost four fold greater in octogenarians as compared with the younger cohort (13.9% vs. 3.7%, P < 0.01).

Conclusions: CRT appears to be safe in the very elderly despite extensive co-morbidity, and in particular frequent severe CKD. Symptomatic improvement appears to be meaningful. Strategies to increase the appropriate identification of elderly patients with CHF who are potential candidates for CRT are required.

Keywords: Cardiac resynchronisation therapy; Heart failure; Left ventricular dysfunction; Safety; The elderly.

PubMed Disclaimer

References

    1. National Heart Failure Audit 2012/2013 British Society for Heart Failure Home Page. www.ucl.ac.uk/nicor/audits/heartfailure/documents/annualreports/hfannual... (accessed June 20, 2015)
    1. de Giuli F, Khaw KT, Cowie MR, et al. Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom. Eur J Heart Fail. 2005;7:295–302. - PubMed
    1. CIBIS-II Investigators and Committee The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13. - PubMed
    1. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Eng J Med. 1987;316:1429–1435. - PubMed
    1. The RALES Trial Stufy Group Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) Am J Cardiol. 1996;78:902–907. - PubMed

LinkOut - more resources